曲贝替定 trabectedin

Drug Class

Alkylating agent / DNA binder

Mechanism

Binds to the minor groove of DNA, bending the helix toward the major groove, interfering with transcription regulation and cell division pathways.

Approved Indication

FDA-approved for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.

What This Means For Patients

曲贝替定 is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2015) — Sources
• EMA — Approved (2007) — Sources

Pivotal Clinical Evidence

• ET743-SAR-3007 — Demetri et al., J Clin Oncol 2016 (NCT01343277) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207953s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/yondelis